www.stocktitan.net
Company Launches PRIME Phase 1b Study for Gemini in Chronic Kidney Disease Patients
726+ Words Refined into 3 Facts by AI • 1 source • 4h ago
Show Full Summary
- Revelation Biosciences has initiated its PRIME Phase 1b clinical study to investigate Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
- The U.S. multi-site placebo-controlled study will evaluate escalating doses across five cohorts, enrolling up to 40 patients.
- CEO James Rolke emphasized that maintaining Nasdaq listing helps preserve stockholder liquidity and provides access to capital.
- The company plans to share study results with shareholders at each milestone throughout 2025.
The sources of this summary are listed below. Click to view.